http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-545495-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
filingDate | 2004-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c372270badc61055ed43c3883f15f247 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee87f0968f13b534a14230e0c9a7bc59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f98dd86a4916368c5889d9df701aab67 |
publicationDate | 2010-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | NZ-545495-A |
titleOfInvention | Use of modified cyclosporins for the treatment of Hepatitis C and HCV disorders |
abstract | Disclosed is the use of a cyclosporin in the preparation of a pharmaceutical composition for preventing or treating Hepatitis C infections or HCV induced disorders, wherein the cyclosporin (i) binds to human recombinant cyclophilin with a binding ratio of less than 0.7; and (ii) has an activity in the Mixed Lymphocyte Reaction of not more than 5% that of cyclosporin A. The cyclosporin is a compound of formula 1a in which: WÆ is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt; X is alpha-Abu, Val, Thr, Nva or O-methyl threonine (MeOThr); R' is Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl); Y' is MeLeu, y-hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle, MeaThr; N-ethyIVal, N-ethyille, N-ethyIThr, N-ethyIPhe, N-ethylTyr, N-ethyIThr(Oacetyl) Z is Val, Leu, MeVal or MeLeu; and Q' is MeLeu, y-hydroxy-MeLeu or MeAla. or a pharmaceutically acceptable salt thereof. Further disclosed is the use of the cyclosporin as described above in combination with a co-agent selected from an agent having anti-HCV properties, an anti-viral agent, an inhibitor of HCV-encoded factors, an anti-fibrotic agent, an immune modulating agent or a S1P receptor agonist in the preparation of a pharmaceutical composition. |
priorityDate | 2003-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 381.